YAP1 (BSB-146), MMab

Summary and Explanation

YAP1 antibody It is frequently overexpressed in Mammary carcinoma, Glioblastoma and Squamous Cell Carcinoma, Pancreatic, Oral, Cervical, Ovarian and Lung Cancers. YAP1 has been found to be expressed in fetal and adult brain regions known to harbor neural progenitor cells but there was little YAP1 immunoreactivity in the adult cerebral cortex. YAP1 protein was also readily detected in the nuclei of human brain tumors. In Medulloblastoma, expression varied between histologic subtypes and was most prominent in Nodular/Desmoplastic tumors. In Gliomas it was frequently expressed in infiltrating Astrocytomas and Oligodendrogliomas, but rarely in Pilocytic Astrocytomas. YAP1 antibody immunoreactivity has been found in the nuclei of tumor cells in 64.8% of Clear Cell Renal Cell Carcinoma (ccRCC) patients, whereas only 24.1% of tumors revealed cytoplasmic YAP1 expression with ccRCC patients having cytoplasmic YAP1 immunoexpression had significantly shorter OS (median = 26.8 months) than patients without cytoplasmic YAP1 and concluded that increased cytoplasmic YAP1 (HR = 4.53) and decreased LATS1 immunoreactivity levels (HR = 0.90) were associated with worse prognosis, being independent prognostic factors. These results suggest that YAP1 and LATS1 can be considered as new prognostic factors in ccRCC.

---

Synonyms: yap1, yap-1, Yes-Associated Protein 1, anti-yap1, anti-yap-1